Clinical Trials
19 trialsNCT03740165 2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03517449 2026-03-19
MK-3475-775
Eisai Inc.
Phase 3 Completed
NCT03635567 2026-02-04
KEYNOTE-826
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05342636 2025-12-17
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT04428151 2025-12-04
LEAP-009
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04489888 2025-06-19
MK-3475-B10
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT03631784 2025-03-25
KEYNOTE-799
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02819518 2024-11-27
KEYNOTE-355
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02775435 2024-10-08
KEYNOTE-407
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03875092 2024-10-01
KEYNOTE-407
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02735239 2024-03-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT03850444 2023-09-18
Keynote 042
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03933449 2023-03-29
KEYNOTE-181
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02564263 2023-03-13
KEYNOTE-181
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02549209 2022-03-02
Pembro/Carbo/Taxol in Endometrial Cancer
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT02256436 2021-09-20
MK-3475-045
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02622074 2020-09-10
KEYNOTE 173
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01704287 2020-05-18
KEYNOTE 002
Merck Sharp & Dohme LLC
Phase 2 Completed